Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.
